---
document_datetime: 2025-03-17 15:33:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/lazcluze-epar-all-authorised-presentations_en.pdf
document_name: lazcluze-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0535079
conversion_datetime: 2025-12-20 00:51:50.703406
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate Packaging     | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-------------------------|-------------|
| EU/1/24/1886/001 | Lazcluze          | 80 mg      | Film-coated tablet    | Oral use                  | blister (PVC/PCTFE/alu) | 56 tablets  |
| EU/1/24/1886/002 | Lazcluze          | 80 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)           | 60 tablets  |
| EU/1/24/1886/003 | Lazcluze          | 80 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)           | 90 tablets  |
| EU/1/24/1886/004 | Lazcluze          | 240 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PCTFE/alu) | 14 tablets  |
| EU/1/24/1886/005 | Lazcluze          | 240 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PCTFE/alu) | 28 tablets  |
| EU/1/24/1886/006 | Lazcluze          | 240 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)           | 30 tablets  |